APRL5 Antibody

Shipped with Ice Packs
In Stock

Description

Potential Nomenclature Clarification

The closest matching targets in current immunology research involve APRIL (A Proliferation-Inducing Ligand), a TNF superfamily member (TNFSF13) critical for B-cell survival and antibody class switching. Key receptors include:

  • BCMA (B-Cell Maturation Antigen)

  • TACI (Transmembrane Activator and Calcium Modulator)

  • HSPG (Heparan Sulfate Proteoglycans)

No "APRL5" gene, protein, or antibody is recognized in NCBI, UniProt, or IEDB databases .

Clinically Relevant APRIL-Targeted Antibodies

The following table summarizes APRIL-directed agents in development or approved therapy:

Antibody NameTarget(s)MechanismClinical StageKey Findings
hAPRIL.01AAPRILBlocks TACI/BCMA bindingPreclinicalReduces CLL cell survival in vitro
AtaciceptAPRIL + BAFFTACI-Fc fusion proteinPhase III (SLE/LN)60% mature B-cell reduction
VAY736 (Ianalumab)BAFF-RDepletes B-cells via ADCCApproved (RA, SLE)Targets BAFF-R, spares APRIL signaling

Key functional distinctions:

  • APRIL-specific inhibitors (e.g., hAPRIL.01A) preferentially block survival signals in CD5+ B1 cells and multiple myeloma .

  • Dual BAFF/APRIL inhibitors (e.g., Atacicept) show broader immunosuppression but increased infection risks .

In vitro effects

  • CLL Survival Blockade: Primary CLL cells undergo apoptosis within 72hrs when treated with APRIL-neutralizing antibodies (EC₅₀ = 0.8 nM) .

  • Receptor Internalization: APRIL binding induces BCMA/TACI internalization, prevented by hAPRIL.01A (p < 0.01 vs control) .

In vivo models

  • APRIL-Tg Mice: Develop CLL-like CD5+ B1 expansions; antibody treatment reduces splenomegaly by 42% (p < 0.001) .

  • Autoimmunity: APRIL inhibition increases regulatory B-cells (CD19+CD24hiCD38hi) by 3.2-fold in RA models .

Developmental Challenges

  • Redundancy: BAFF compensates for APRIL blockade in TACI-low malignancies .

  • HSPG Competition: Heparan sulfate binding complicates antibody targeting in solid tumors .

Product Specs

Buffer
Preservative: 0.03% ProClin 300; Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Form
Liquid
Lead Time
14-16 week lead time (made-to-order)
Synonyms
APRL5; At3g03860; F20H23.9; 5'-adenylylsulfate reductase-like 5; Adenosine 5'-phosphosulfate reductase-like 5; APR-like 5; AtAPRL5
Target Names
APRL5
Uniprot No.

Target Background

Database Links

KEGG: ath:AT3G03860

STRING: 3702.AT3G03860.1

UniGene: At.18353

Subcellular Location
Membrane; Single-pass membrane protein.

Q&A

Given the lack of specific information on "APRL5 Antibody" in the search results, I will create a general framework for FAQs related to antibody research, focusing on aspects relevant to academic research scenarios. This framework can be adapted to specific antibodies like APRL5 once more detailed information becomes available.

A:

To study the effects of an antibody like APRL5, you should:

  • Identify the Target: Determine the specific antigen or protein that the antibody binds to.

  • Choose a Model System: Select an appropriate biological model (e.g., cell culture, animal model) that reflects the biological context of interest.

  • Experimental Controls: Include controls to account for non-specific binding or effects.

  • Quantitative Analysis: Use techniques like ELISA, Western blot, or flow cytometry to quantify antibody binding and its effects.

A:

When selecting and validating an antibody:

  • Specificity: Ensure the antibody specifically binds to the target antigen without cross-reactivity.

  • Sensitivity: Choose an antibody with high sensitivity to detect the target in various conditions.

  • Validation: Validate the antibody using multiple methods (e.g., Western blot, immunofluorescence) to confirm its specificity and utility.

A:

To analyze and interpret data:

  • Statistical Analysis: Use appropriate statistical tests to compare groups and assess significance.

  • Data Replication: Ensure results are reproducible across multiple experiments.

  • Literature Comparison: Compare findings with existing literature to contextualize results and address contradictions.

A:

To enhance antibody affinity or predict binding sites:

  • Machine Learning Models: Utilize models like AbRFC to predict affinity-enhancing mutations .

  • Computational Tools: Employ tools that simulate antibody-antigen interactions to predict optimal binding sites.

A:

When using antibodies in immunoassays:

  • Optimize Conditions: Optimize assay conditions (e.g., antibody concentration, incubation time) for best performance.

  • Control for Variability: Use controls to account for variability in antibody binding or assay conditions.

  • Standardization: Standardize protocols across experiments to ensure comparability of results.

A:

To develop a focused research question:

  • Literature Review: Conduct a thorough literature review to identify gaps in current knowledge.

  • Specificity: Ensure the question is specific, focused, and answerable within the scope of your study.

  • Realism: Consider the feasibility of the study in terms of time, budget, and available resources .

A:

To map the epitope recognized by an antibody:

  • Domain Deletion Mutants: Use domain-deleted mutants of the antigen to identify the specific region recognized by the antibody.

  • Peptide Arrays: Employ peptide arrays to pinpoint the exact epitope sequence.

  • Computational Modeling: Utilize computational models to predict potential epitopes based on antibody-antigen interactions.

A:

To maintain antibody stability:

  • Temperature Control: Store antibodies at appropriate temperatures (e.g., -20°C for long-term storage).

  • Freeze-Thaw Cycles: Minimize freeze-thaw cycles to prevent degradation.

  • Buffer Conditions: Store antibodies in buffers that maintain their stability and activity.

A:

To collaborate and share resources effectively:

  • Open Communication: Maintain open communication among team members to share protocols and results.

  • Standardized Protocols: Use standardized protocols to ensure consistency across different labs.

  • Resource Sharing Platforms: Utilize platforms or repositories for sharing antibodies, protocols, and data.

A:

Emerging trends include:

  • Machine Learning Integration: Using machine learning to predict and enhance antibody affinity .

  • Single-Cell Analysis: Applying single-cell techniques to understand antibody responses at the cellular level.

  • Therapeutic Antibodies: Developing antibodies for therapeutic applications, including cancer and infectious diseases .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.